Background and Relevance
The IMSS-Bienestar, a Mexican social security institute responsible for healthcare programs, is currently dealing with significant financial challenges. These issues have resulted in unpaid debts to pharmaceutical companies since 2023, due to administrative and operational failures that have hindered timely payments.
José Luis García Rodríguez, president of the Mexican Association of Institutional Health Distribution (Asmedis), a non-profit organization representing companies involved in medicine and medical device distribution, has highlighted the critical nature of this problem. He emphasized that resolving these financial, operational, and public administration issues within IMSS-Bienestar is essential for the success of the upcoming 2027-2028 procurement process.
Current Situation and Impact
García Rodríguez pointed out that some suppliers find it unsustainable to continue financing a system that does not pay them on time. The consolidated purchase for 2027-2028, which is currently underway, aims to acquire 3,831 keys and a substantial volume for IMSS-Bienestar.
He described the situation as dire, stating that pharmaceutical companies are ending their fiscal years with high debts due to IMSS-Bienestar’s failure to pay. García Rodríguez mentioned that paperwork is scattered, making it difficult to determine the exact amount owed.
In contrast, the Instituto Mexicano del Seguro Social (IMSS) has fulfilled its payment obligations and remains current. The ISSSTE’s compliance rate is approximately 90%, according to García Rodríguez.
Problems and Delays
García Rodríguez explained that scheduling appointments for reviews and bill deliveries remains problematic. The offices responsible for operations are overwhelmed with paperwork, causing significant delays in processing.
He further elaborated that formal processes have not resolved the situation, as IMSS-Bienestar has disregarded conciliation processes with the Secretary of Anticorruption and Good Governance. As of January 2, there were no payments made, he noted.
Asmedis’s Perspective
The president of Asmedis, which represents companies involved in medicine and medical device distribution, mentioned that the unpaid debts span from 2023 to 2025. He did not disclose the exact amount of outstanding payments.
García Rodríguez emphasized that the lack of a proper cycle from contracting, order issuance, delivery scheduling, and invoice acceptance for payment has led to inefficiencies across the board.
Key Questions and Answers
- What is the main issue faced by IMSS-Bienestar? The primary concern is the accumulated debt with pharmaceutical suppliers due to administrative and operational failures.
- Why is this issue critical for the upcoming procurement process? Addressing these financial, operational, and public administration issues within IMSS-Bienestar is essential for the success of the 2027-2028 procurement process.
- How has this situation affected pharmaceutical companies? Companies are ending their fiscal years with high debts due to IMSS-Bienestar’s failure to pay on time.
- What are the problems with scheduling appointments and bill deliveries? The offices responsible for operations are overwhelmed with paperwork, causing significant delays in processing.
- What has been the outcome of formal processes to resolve this issue? Formal processes have not resolved the situation, as IMSS-Bienestar has disregarded conciliation processes with the Secretary of Anticorruption and Good Governance.
